We are pleased to announce that Dr. Victor Stone from Takeda Ventures was elected and appointed as a new director at our Ordinary General Meeting of Shareholders on June 16, 2021.
ARTham Therapeutics Presents Data from Phase 2 Study of ART-001 at International Conference on Vascular Anomalies 2023
ART-001 phase II study met its primary endpoint of response rate in patients with slow-flow vascular malformations
Kaken Pharmaceutical to acquire ARTham Therapeutics
ARTham announces first patient dosed in Phase 2 clinical trial of ART-648 in patients with bullous pemphigoid.
ARTham announces first patient dosed in Phase 2 clinical trial of ART-001 in patients with slow-flow vascular malformations.